Published in Patholog Res Int on July 27, 2011
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
MicroRNAs - Important Molecules in Lung Cancer Research. Front Genet (2012) 0.90
GSTT1 null genotype contributes to lung cancer risk in asian populations: a meta-analysis of 23 studies. PLoS One (2013) 0.88
Non-coding RNAs in lung cancer. Oncoscience (2014) 0.83
MicroRNA aberrations: An emerging field for gallbladder cancer management. World J Gastroenterol (2016) 0.81
Genetic Variations in Key MicroRNAs are Associated With the Survival of Nonsmall Cell Lung Cancer. Medicine (Baltimore) (2015) 0.76
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
miRBase: tools for microRNA genomics. Nucleic Acids Res (2007) 38.61
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol (2005) 18.94
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev (2006) 15.20
Processing of primary microRNAs by the Microprocessor complex. Nature (2004) 14.59
Phylogenetic shadowing and computational identification of human microRNA genes. Cell (2005) 13.24
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev (2007) 10.15
MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 8.21
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol (2010) 5.92
MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A (2011) 4.11
Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet (2007) 4.08
Lung cancer. Lancet (2000) 3.93
Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell (2010) 3.72
MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res (2007) 3.68
Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest (2008) 3.53
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol (2009) 3.47
Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res (2010) 3.21
MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest (2010) 2.87
Regression of murine lung tumors by the let-7 microRNA. Oncogene (2009) 2.83
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
The promise of microRNA replacement therapy. Cancer Res (2010) 2.68
MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer (2009) 2.56
Epigenetics and microRNAs. Pediatr Res (2007) 2.52
Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res (2009) 2.50
Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res (2007) 2.48
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest (2010) 2.37
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol (2008) 2.29
Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer (2010) 2.20
MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene (2011) 2.09
ATP-dependent human RISC assembly pathways. Nat Struct Mol Biol (2009) 2.04
MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer (2009) 1.99
Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res (2008) 1.98
EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res (2010) 1.95
A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev (2009) 1.93
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics (2009) 1.88
Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother (2010) 1.82
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res (2010) 1.81
Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer (2010) 1.72
Interobserver variability in histopathologic subtyping and grading of pulmonary adenocarcinoma. Cancer (1993) 1.72
miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res (2010) 1.67
let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci (2011) 1.65
MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer (2011) 1.55
Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis (1970) 1.51
Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis (2008) 1.51
MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol (2011) 1.42
MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci (2008) 1.41
The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res (2011) 1.29
MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol (2010) 1.13
Therapeutic microRNA strategies in human cancer. AAPS J (2009) 1.10
Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J Surg Oncol (2010) 1.05
Nucleobase and ribose modifications control immunostimulation by a microRNA-122-mimetic RNA. J Am Chem Soc (2011) 1.01
The molecular basis of lung cancer: molecular abnormalities and therapeutic implications. Respir Res (2003) 0.97
Association of a common AGO1 variant with lung cancer risk: a two-stage case-control study. Mol Carcinog (2010) 0.97
Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clin Lung Cancer (2011) 0.96
Tumor-targeted RNA-interference: functional non-viral nanovectors. Am J Cancer Res (2011) 0.92
Progress in the epidemiological understanding of gene-environment interactions in major diseases: cancer. C R Biol (2007) 0.91
Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival. Br J Cancer (2010) 0.89
Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist (2010) 0.88
A novel cationic liposome formulation for efficient gene delivery via a pulmonary route. Nanotechnology (2011) 0.80
Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res (2004) 8.41
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet (2002) 2.46
Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurosci (2006) 1.85
Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J Nucl Med (2006) 1.83
Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep (2002) 1.80
Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet (2006) 1.78
Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol (2003) 1.73
Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J Immunol (2007) 1.70
Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines. Int J Cancer (2004) 1.68
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood (2007) 1.63
Characterization and intracellular localization of the Epstein-Barr virus protein BFLF2: interactions with BFRF1 and with the nuclear lamina. J Virol (2005) 1.62
BFRF1 of Epstein-Barr virus is essential for efficient primary viral envelopment and egress. J Virol (2005) 1.59
Assignment of a locus for autosomal dominant idiopathic scoliosis (IS) to human chromosome 17p11. Hum Genet (2002) 1.57
Regulated expression of MUC1 epithelial antigen in erythropoiesis. Br J Haematol (2003) 1.56
Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. J Am Coll Cardiol (2011) 1.55
Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc Natl Acad Sci U S A (2002) 1.54
NF1 gene mutations represent the major molecular event underlying neurofibromatosis-Noonan syndrome. Am J Hum Genet (2005) 1.53
TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells. J Biol Chem (2012) 1.50
Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene (2004) 1.46
Comment on: isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer (2011) 1.44
Prognostic significance of reverse transcriptase-polymerase chain reaction-negative sentinel nodes in malignant melanoma. Ann Surg Oncol (2003) 1.42
Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J (2006) 1.37
Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. Exp Cell Res (2004) 1.35
Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study. BMC Med Genet (2006) 1.30
Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res (2007) 1.26
HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol (2010) 1.24
Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer (2002) 1.22
Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J (2007) 1.20
The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J (2007) 1.19
Pre-TCR-triggered ERK signalling-dependent downregulation of E2A activity in Notch3-induced T-cell lymphoma. EMBO Rep (2003) 1.18
retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines. Cancer Res (2002) 1.17
Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat (2004) 1.14
p38 MAPK activation controls the TLR3-mediated up-regulation of cytotoxicity and cytokine production in human NK cells. Blood (2004) 1.14
Suppression of dendritic cell differentiation through cytokines released by Primary Effusion Lymphoma cells. Immunol Lett (2008) 1.10
Celecoxib induces MRP-4 in lung cancer cells: therapeutic implications. J Clin Oncol (2007) 1.10
SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood (2002) 1.09
Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol (2003) 1.09
The role of PC-1 and ACE genes in diabetic nephropathy in type 1 diabetic patients: evidence for a polygenic control of kidney disease progression. Nephrol Dial Transplant (2002) 1.08
Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma. Cancer Cell Int (2004) 1.08
HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition: practical implications of the HLA molecular typing. J Biomed Sci (2012) 1.08
Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS One (2012) 1.07
Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther (2009) 1.06
EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. Mol Carcinog (2003) 1.06
PKC theta mediates pre-TCR signaling and contributes to Notch3-induced T-cell leukemia. Oncogene (2005) 1.06
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. Int J Cancer (2010) 1.05
Clinical features and outcome of familial chronic lymphocytic leukemia. Haematologica (2006) 1.05
A variation in 3' UTR of hPTP1B increases specific gene expression and associates with insulin resistance. Am J Hum Genet (2002) 1.05
Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fcepsilon RI and Syk in RBL cells. J Biol Chem (2002) 1.05
Vaginoplasty using autologous in vitro cultured vaginal tissue in a patient with Mayer-von-Rokitansky-Kuster-Hauser syndrome. Hum Reprod (2007) 1.04
A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome. Eur J Hum Genet (2004) 1.03
Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res (2005) 1.03
REN: a novel, developmentally regulated gene that promotes neural cell differentiation. J Cell Biol (2002) 1.03
Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration. J Immunol (2003) 1.02
Brain derived neurotrophic factor (BDNF) expression is regulated by microRNAs miR-26a and miR-26b allele-specific binding. PLoS One (2011) 1.01
Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol (2010) 1.01
Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat Disord (2004) 1.01
Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J Immunol (2012) 0.99
Notch3 and canonical NF-kappaB signaling pathways cooperatively regulate Foxp3 transcription. J Immunol (2011) 0.99
Synergistic post-transcriptional regulation of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) by miR-101 and miR-494 specific binding. PLoS One (2011) 0.99
Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol (2010) 0.99
Arf6: a new player in FcgammaRIIIA lymphocyte-mediated cytotoxicity. Blood (2005) 0.98
DiGeorge subtypes of nonsyndromic conotruncal defects: evidence against a major role of TBX1 gene. Eur J Hum Genet (2003) 0.98
UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep (2005) 0.98
Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis. Cell Transplant (2013) 0.98
Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol (2012) 0.98
Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. J Neurochem (2006) 0.97
Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med (2010) 0.97
A comparative analysis of serum and serum-free media for generation of clinical grade DCs. J Immunother (2007) 0.96
Novel Italian family supports clinical and genetic heterogeneity of primary adult-onset torsion dystonia. Mov Disord (2002) 0.96
Elevated levels of miR-145 correlate with SMAD3 down-regulation in cystic fibrosis patients. J Cyst Fibros (2013) 0.96
CIN85 regulates the ligand-dependent endocytosis of the IgE receptor: a new molecular mechanism to dampen mast cell function. J Immunol (2005) 0.96
CRELD1 and GATA4 gene analysis in patients with nonsyndromic atrioventricular canal defects. Am J Med Genet A (2005) 0.95
High prevalence of epilepsy in a village in the Littoral Province of Cameroon. Epilepsy Res (2008) 0.95
Silencing of keratinocyte growth factor receptor restores 5-fluorouracil and tamoxifen efficacy on responsive cancer cells. PLoS One (2008) 0.95
Human herpesvirus 8 (HHV-8) inhibits monocyte differentiation into dendritic cells and impairs their immunostimulatory activity. Immunol Lett (2007) 0.95
PI5KI-dependent signals are critical regulators of the cytolytic secretory pathway. Blood (2007) 0.94
Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells. J Transl Med (2014) 0.94
Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. Neurogenetics (2007) 0.94
Cross talk among Notch3, pre-TCR, and Tal1 in T-cell development and leukemogenesis. Blood (2005) 0.94
Zebrafish embryo proteins induce apoptosis in human colon cancer cells (Caco2). Apoptosis (2006) 0.94
Activation of dendritic cells by tumor cell death. Oncoimmunology (2012) 0.94
Early defect of transforming growth factor β1 formation in Huntington's disease. J Cell Mol Med (2011) 0.93
Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev (2005) 0.93
Hyperthermia enhances CD95-ligand gene expression in T lymphocytes. J Immunol (2005) 0.93
Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol (2005) 0.92
Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J (2005) 0.92
Regulation of the expression of the Epstein-Barr virus early gene BFRF1. Virology (2006) 0.91
Detection of CK19, CK20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease. Oncol Rep (2002) 0.91
A family with autosomal dominant mutilating neuropathy not linked to either Charcot-Marie-Tooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci. Neuromuscul Disord (2002) 0.90
Functional analysis of splicing mutations in exon 7 of NF1 gene. BMC Med Genet (2007) 0.90
Notch, a unifying target in T-cell acute lymphoblastic leukemia? Trends Mol Med (2003) 0.90
15-deoxy-Delta12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-kappaB and early growth response transcription factors. J Immunol (2007) 0.90
Differential response to keratinocyte growth factor receptor and epidermal growth factor receptor ligands of proliferating and differentiating intestinal epithelial cells. J Cell Physiol (2004) 0.90
Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. BMC Cancer (2014) 0.89
Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. Anticancer Res (2011) 0.89
High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res (2005) 0.89
Quantification of small non-coding RNAs allows an accurate comparison of miRNA expression profiles. J Biomed Biotechnol (2009) 0.88
Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells. Cancer Lett (2009) 0.88